News | November 16, 2011

Positive Clinical Study Results for BSP’s HyperQ Technology will be reported in American Journal of Cardiology

November 16, 2011 – Biological Signal Processing (BSP), which develops and manufactures products for the non-invasive, accurate diagnosis of coronary artery disease (CAD), recently announced the successful completion of a comprehensive clinical research study evaluating the performance of the company’s HyperQ technology in diagnosing CAD. An article describing the study and its results was accepted for publication in the American Journal of Cardiology.

The study recruited 996 patients and compared the clinical performance of HyperQ vs. conventional electrocardiogram (ECG) for the detection of CAD, using nuclear imaging as the gold standard. The study was conducted in two major medical centers in Israel – Assuta Medical Center and Sheba Medical Center, and was headed by Tali Sharir, M.D., and professor Pierre Chouraqui.  The major finding reported by the researchers is a 30 percent improvement in the sensitivity of the HyperQ analysis in the detection of CAD when compared to conventional stress ECG. HyperQ analysis also had a lower false alarm rate compared to conventional stress ECG.

The results of this study were also recently presented, together with additional HyperQ related clinical evidence, at a meeting and hearing of the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) in the United States. The MEDCAC meeting on November 9th was convened in order to consider and make recommendations on the use of new ECG signal analysis technologies to detect CAD, and regarding their inclusion in the coverage policies.  MEDCAC is an advisory committee, commissioned by to CMS (Centers for Medicare & Medicaid Services) – the organization responsible for the determination of the services and medical products that will be reimbursed by Medicare and Medicaid, also heavily weighing in on the coverage policies of private insurers in the United States. The MEDCAC committee concluded its discussions with a recommendation encouraging the CMS to include new signal analysis technologies, that are U.S. Food and Drug Administration (FDA) cleared and have shown sufficient clinical evidence, in the coverage policies for cardiac care and diagnosis.

"Appearing before MEDCAC committee is an important milestone in the process of obtaining reimbursement for our products in the U.S.," says Amir Beker, M.D., chairman of BSP, who presented at the hearing. He added, "This endeavor is also backed by a HyperQ large-scale clinical study in three leading U.S. medical centers, The Cleveland Clinic, University of Virginia medical center and Minneapolis Heart Institute Foundation, to collect clinical and economic data in support of BSP's reimbursement campaign in the U.S."

For more information:  www.bspmedical.com

 

Related Content

ScImage and Invia Partnership Announced
News | Cardiac PACS| September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
CZT SPECT camera detectors offered by GE.

A display of CZT SPECT gamma camera detectors at RSNA 2016. These detectors are more sensitive than those used in older cameras, allowing for faster scans or lower radiation dose. 

Feature | Nuclear Imaging| September 19, 2017 | Dave Fornell
Cardiac nuclear myocardial perfusion imaging (MPI) has been a mature area of imaging for years, but has recently star
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging| September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Overlay Init